Background: Environmental and genetic factors are thought to be involved in the pathogenesis of multiple sclerosis (MS). Polymorphisms of tumor necrosis factor (TNF)-α −308 were implicated in MS risk in several case–control association studies. However, the studies have shown inconsistent results.
Objectives: To address the association of G/A polymorphisms of TNF-α −308 with MS risk by meta-analysis.
Methods: Thirteen studies were included. Pooled odds ratios (ORs) together with 95% confidence intervals (CIs) were calculated.
Results: A total of 1870 cases and 2769 controls were included in the meta-analysis. The pooled result indicated that −308 A allele is significantly associated with reduced risk of MS compared with −308 G allele (A vs. G, p = 0.022). The same pattern of the result was also obtained in the contrasts of AA + GA vs. GG (p = 0.008) and GA vs. GG (p = 0.007). For AA vs. GG or AA vs. GA + GG, no significant association was detected most likely caused by very low frequency or non-availability of homozygote genotype AA for all of the studies.
Conclusions: TNF-α −308 A allele is associated with reduced risk of MS.
BjartmarCTrappBD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol2001; 14: 271–278.
2.
LincolnJACookSD. An overview of gene–epigenetic–environmental contributions to MS causation. J Neurol Sci2009; 286: 54–57.
3.
ZuvichRLMcCauleyJLPericak-VanceMAHainesJL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol2009; 21: 328–333.
4.
NavikasVLinkH. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res1996; 45: 322–333.
5.
VassalliP. The pathophysiology of tumor necrosis factors. Annu Rev Immunol1992; 10: 411–452.
6.
WilsonAGSymonsJAMcDowellTLMcDevittHODuffGW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A1997; 94: 3195–3199.
7.
IzadMVodjganiMNiknamMH. Cytokines genes polymorphisms and risk of multiple sclerosis. Am J Med Sci2010; 339: 327–331.
8.
RisticSLovrecicLStarcevic-CizmarevicN. Tumor necrosis factor-alpha-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur Neurol2007; 57: 203–207.
9.
Kamali-SarvestaniENiksereshtAAflakiESarvariJGharesi-FardB. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol Scand2007; 115: 161–166.
10.
ForteGIRagonesePSalemiG. Search for genetic factors associated with susceptibility to multiple sclerosis. Ann N Y Acad Sci2006; 1067: 264–269.
11.
MihailovaSIvanovaMMihaylovaAQuinLMikovaONaumovaE. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol2005; 168: 138–143.
12.
LuomalaMLehtimakiTHuhtalaH. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand2003; 108: 396–400.
13.
DrulovicJPopadicDMesarosS. Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. Eur Neurol2003; 50: 25–29.
14.
Fernandes FilhoJAVedelerCAMyhrKMNylandHPandeyJP. TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity2002; 35: 377–380.
15.
Fernandez-ArqueroMArroyoRRubioA. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology1999; 53: 1361–1363.
16.
MyckoMKowalskiWKwinkowskiM. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol1998; 84: 198–206.
17.
WingerchukDLiuQSobellJSommerSWeinshenkerBG. A population-based case–control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology1997; 49: 626–628.
18.
HuizingaTWWestendorpRGBollenEL. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol1997; 72: 149–153.
19.
HeBNavikasVLundahlJSoderstromMHillertJ. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol1995; 63: 143–147.
20.
HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med2002; 21: 1539–1558.
21.
ZintzarasEChatzoulisDZKarabatsasCHStefanidisI. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet2005; 50: 267–275.
22.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ1997; 315: 629–634.
23.
ComabellaMCraigDWCamina-TatoM. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One2008; 3: e3490–e3490.
24.
LundmarkFDuvefeltKIacobaeusE. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet2007; 39: 1108–1113.
25.
HaflerDACompstonASawcerS. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med2007; 357: 851–862.
26.
GregorySGSchmidtSSethP. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet2007; 39: 1083–1091.
27.
HoffjanSAkkadDA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes2010; 24: 237–243.
28.
BushWSSawcerSJde JagerPL. Evidence for polygenic susceptibility to multiple sclerosis—the shape of things to come. Am J Hum Genet2010; 86: 621–625.
29.
BahreiniSAJabalameliMRSaadatniaMZahednasabH. The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility. J Neuroimmunol2010in press.
30.
De JagerPLJiaXWangJ. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet2009; 41: 776–782.
31.
van OostenBWBarkhofFTruyenL. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology1996; 47: 1531–1534.
32.
FromontADe SezeJFleuryMCMaillefertJFMoreauT. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine2009; 45: 55–57.
33.
SicotteNLVoskuhlRR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology2001; 57: 1885–1888.
34.
MohanNEdwardsETCuppsTR. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum2001; 44: 2862–2869.
35.
SiddiquiMAScottLJ. Spotlight on infliximab in Crohn disease and rheumatoid arthritis. BioDrugs2006; 20: 67–70.
36.
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology1999; 53: 457–465.
